Antonio Fernandez, MD
Cardiovascular Disease · Hartford, CTNPI 1417187709
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Amgen accounts for 63.6% of it on its own, with 28 other manufacturers making up the rest. Among cardiovascular disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $480.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$72K
- Kaneka Medical America LLC$34K
- Novartis$2K
- Eli Lilly$2K
- Novo Nordisk$582
- Lilly USA, LLC$330
- plus $2K from 23 others
Across 5 payments — averaging $14,203 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$71K
What the payments were for
- Consulting fees$30,84327%
- Speaking & faculty fees$62,70455%
- Travel & lodging$7,5477%
- Food & beverage$8,6998%
- Education$2340%
- Other$3,0003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 122 | $71,893 |
| Kaneka Medical America LLC | 9 | $34,264 |
| Novartis | 9 | $2,068 |
| Eli Lilly | 19 | $2,061 |
| Novo Nordisk | 11 | $582 |
| Lilly USA, LLC | 8 | $330 |
| Chiesi USA, Inc. | 2 | $324 |
| Johnson & Johnson | 9 | $251 |
| E.r. Squibb & Sons, L.L.C. | 4 | $156 |
| ZOLL Medical Corporation | 1 | $152 |
| Ionis Pharmaceuticals, Inc. | 1 | $121 |
| Abbott | 1 | $115 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $115 |
| AstraZeneca | 4 | $93 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $68 |
| Boehringer Ingelheim | 3 | $56 |
| Abiomed | 2 | $53 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Pfizer | 2 | $37 |
| Lantheus Medical Imaging, Inc. | 2 | $35 |
| Bardy Diagnostics, Inc. | 2 | $30 |
| Impulse Dynamics (USA) Inc. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Preventice Services, LLC | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $19 |
| Akcea Therapeutics, Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 3 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$69,530
- Apheresis Machine$15,101
- Liposober$3,000
- LEQVIO$1,900
- JUXTAPID$300
- XARELTO$129
- TRYNGOLZA$121
- Ozempic$116
- CardioMEMS HF System$115
How this compares
$113,028 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 119 | $83,701 |
| Praluent PenAlirocumab | 88 | $56,007 |
| JardianceEmpagliflozin | 13 | $15,314 |
| EliquisApixaban | 16 | $15,101 |
| NexletolBempedoic Acid | 16 | $10,528 |
| BrilintaTicagrelor | 16 | $8,232 |
| Ezetimibe | 42 | $1,110 |
| Icosapent Ethyl | 14 | $992 |
| Rosuvastatin Calcium | 37 | $362 |
| Amlodipine Besylate | 11 | $110 |
| Losartan Potassium | 21 | $107 |
| Atorvastatin Calcium | 14 | $104 |
| Metoprolol Tartrate | 16 | $99 |
| Metoprolol Succinate | 13 | $70 |
| Lisinopril | 15 | $42 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $56 | $15,31413 claims |
| PfizerEliquis | $37 | $15,10116 claims |
| Esperion Therapeutics, Inc.Nexletol | $41 | $10,52816 claims |
| AstraZenecaBrilinta | $93 | $8,23216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 415 cardiovascular disease providers in Connecticut.
Other cardiovascular disease in Hartford
- Stephanie SaucierHartford$243K
- Paul ThompsonHartford$108K
- Richard SoucierHartford$97K
- Atique MirzaHartford$29K
- Sean McMahonHartford$23K
- Lonny ReismanHartford$22K
- David HenryHartford$13K
- Nihar DesaiNew Haven$1.4M
- Brett NowlanBloomfield$798K
- Jeffery TestaniNew Haven$546K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.